iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

9 Months Ended

Mar. 31, 2021

Earnings (Loss) Per Common Share [Abstract]

Schedule of Earnings (loss) Per Share, Basic and Diluted


		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2021			2020			2021			2020
Basic and diluted numerator:

Net loss attributable to iBio, Inc.		$	(7,661)		$	(4,676)		$	(23,323)		$	(12,901)
Deemed dividends – down round of Series A Preferred and Series B Preferred			—			—			—			(21,560)
Preferred stock dividends – iBio CMO Preferred Tracking Stock			(64)			(65)			(195)			(196)
Net loss available to iBio, Inc. stockholders		$	(7,725)		$	(4,741)		$	(23,518)		$	(34,657)

Basic and diluted denominator:

Weighted-average common shares outstanding			215,539			79,917			188,493			47,018

Per share amount		$	(0.04)		$	(0.06)		$	(0.12)		$	(0.74)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


		March 31,
		2021		2020
		(in thousands)
Stock options		5,083		2,158
Series A Preferred		—		—
Series B Preferred		—		28,925
Restricted stock units		644		41
Shares excluded from the calculation of diluted loss per share		5,727		31,124